September 21, 2010
Phenex receives 6 M Euro (7,8 M USD) in its Series C financing round
The Nuclear Receptor specialist company invests additional money into its R&D programs in NASH (FXR)…
July 2, 2009
Phenex receives 1.4 Mio Euro BioChance Grant
Phenex AG develops novel indications for FXR-targeted drugs and wins Prof. Dr. Michael Trauner as…
December 3, 2008
Phenex AG and Biogen Idec enter into a milestone-based target to lead collaboration
Biogen Idec uses Phenex´ expertise to identify novel ligands for an undisclosed nuclear receptor Ludwigshafen,…
October 2, 2008
Phenex AG closes 11,5 M USD (8,2 M Euro) financing round
A Syndicate of institutional and private investors provides funding for the development of Phenex´ drug…
Contact
Waldhofer Str. 104
69123 Heidelberg, Germany
Phone: +49 6221 65282-0
Fax: +49 6221 65282-10
Dr. Claus Kremoser
Thomas Hoffmann
mailto: info@phenex-pharma.com
About Phenex Pharmaceuticals AG
Phenex is a privately held drug discovery and development company headquartered in Ludwigshafen with a research site in Heidelberg. The biopharmaceutical company can now build on nineteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex´s R&D activities are centered around diseases of liver such as NASH and cancer.
